Do analysts prefer RLMD or RFL?

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 177.14%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BIOA or RFL?

BioAge Labs presently has a consensus target price of $36.57, indicating a potential upside of 278.98%. Given BioAge Labs' stronger consensus rating and higher possible upside, research analysts clearly believe BioAge Labs is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BIOA or RFL?

Rafael has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAge Labs $8.99M 49.27 -$80.61M -$2.38 N/A Rafael $980K 133.71 -$30.52M -$0.68 N/A

Is BIOA or RFL more profitable?

BioAge Labs has a net margin of -912.26% compared to Rafael's net margin of -3,321.74%. BioAge Labs' return on equity of -28.99% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets BioAge Labs -912.26% -28.99% -27.09% Rafael -3,321.74% -41.27% -35.32%

Do analysts rate RFL or CGC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has stronger earnings and valuation, RFL or CGC?

Rafael has higher earnings, but lower revenue than Canopy Growth. Rafael is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rafael $980K 133.71 -$30.52M -$0.68 N/A Canopy Growth $293.63M 1.53 -$190.29M -$0.45 N/A

Is RFL or CGC more profitable?

Canopy Growth has a net margin of -65.33% compared to Rafael's net margin of -3,321.74%. Canopy Growth's return on equity of -21.91% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% Canopy Growth -65.33% -21.91% -14.34%

Do analysts prefer FENC or RFL?

Adherex Technologies presently has a consensus target price of $17.00, indicating a potential upside of 38.55%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adherex Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer RFL or AVIR?

Atea Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 30.60%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atea Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Rafael (RFL) Competitors

$2.52 +0.15 (+6.33%)

As of 08/28/2026 03:57 PM Eastern

Compare

RFL vs. RLMD, BIOA, CGC, FENC, and AVIR

Should you buy Rafael stock or one of its competitors? Rafael's main competitors and comparable companies include Relmada Therapeutics (RLMD), BioAge Labs (BIOA), Canopy Growth (CGC), Adherex Technologies (FENC), and Atea Pharmaceuticals (AVIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Rafael compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 32.9% of Rafael shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 177.14%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Relmada Therapeutics had 5 more articles in the media than Rafael. MarketBeat recorded 5 mentions for Relmada Therapeutics and 0 mentions for Rafael. Relmada Therapeutics' average media sentiment score of 1.63 beat Rafael's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relmada Therapeutics	Very Positive
Rafael	Neutral

Relmada Therapeutics has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Rafael	-3,321.74%	-41.27%	-35.32%

Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Rafael has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Rafael has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Rafael	$980K	133.71	-$30.52M	-$0.68	N/A

Summary

Relmada Therapeutics beats Rafael on 9 of the 16 factors compared between the two stocks.

How does Rafael compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

BioAge Labs presently has a consensus target price of $36.57, indicating a potential upside of 278.98%. Given BioAge Labs' stronger consensus rating and higher possible upside, research analysts clearly believe BioAge Labs is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.3% of Rafael shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by company insiders. Comparatively, 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioAge Labs has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Rafael has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Rafael has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	49.27	-$80.61M	-$2.38	N/A
Rafael	$980K	133.71	-$30.52M	-$0.68	N/A

In the previous week, BioAge Labs had 2 more articles in the media than Rafael. MarketBeat recorded 2 mentions for BioAge Labs and 0 mentions for Rafael. BioAge Labs' average media sentiment score of 1.82 beat Rafael's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Overall Sentiment
BioAge Labs	Very Positive
Rafael	Neutral

BioAge Labs has a net margin of -912.26% compared to Rafael's net margin of -3,321.74%. BioAge Labs' return on equity of -28.99% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
Rafael	-3,321.74%	-41.27%	-35.32%

Summary

BioAge Labs beats Rafael on 10 of the 16 factors compared between the two stocks.

How does Rafael compare to Canopy Growth?

Rafael (NYSE:RFL) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Canopy Growth has a net margin of -65.33% compared to Rafael's net margin of -3,321.74%. Canopy Growth's return on equity of -21.91% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Canopy Growth	-65.33%	-21.91%	-14.34%

Rafael has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Rafael has higher earnings, but lower revenue than Canopy Growth. Rafael is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$980K	133.71	-$30.52M	-$0.68	N/A
Canopy Growth	$293.63M	1.53	-$190.29M	-$0.45	N/A

11.3% of Rafael shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 0.4% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Canopy Growth had 5 more articles in the media than Rafael. MarketBeat recorded 5 mentions for Canopy Growth and 0 mentions for Rafael. Canopy Growth's average media sentiment score of 0.74 beat Rafael's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Rafael	Neutral
Canopy Growth	Positive

Summary

Canopy Growth beats Rafael on 11 of the 15 factors compared between the two stocks.

How does Rafael compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Adherex Technologies has a net margin of -6.09% compared to Rafael's net margin of -3,321.74%. Adherex Technologies' return on equity of -5.71% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Rafael	-3,321.74%	-41.27%	-35.32%

Adherex Technologies has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Rafael has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 32.9% of Rafael shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Adherex Technologies presently has a consensus target price of $17.00, indicating a potential upside of 38.55%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Adherex Technologies has higher revenue and earnings than Rafael. Adherex Technologies is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$59.22M	7.26	-$9.74M	-$0.13	N/A
Rafael	$980K	133.71	-$30.52M	-$0.68	N/A

In the previous week, Adherex Technologies had 5 more articles in the media than Rafael. MarketBeat recorded 5 mentions for Adherex Technologies and 0 mentions for Rafael. Adherex Technologies' average media sentiment score of 0.96 beat Rafael's score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Positive
Rafael	Neutral

Summary

Adherex Technologies beats Rafael on 13 of the 16 factors compared between the two stocks.

How does Rafael compare to Atea Pharmaceuticals?

Rafael (NYSE:RFL) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Rafael. MarketBeat recorded 1 mentions for Atea Pharmaceuticals and 0 mentions for Rafael. Atea Pharmaceuticals' average media sentiment score of 1.89 beat Rafael's score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Rafael	Neutral
Atea Pharmaceuticals	Very Positive

11.3% of Rafael shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rafael has higher revenue and earnings than Atea Pharmaceuticals. Rafael is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$980K	133.71	-$30.52M	-$0.68	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Atea Pharmaceuticals has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Rafael has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Atea Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 30.60%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Atea Pharmaceuticals beats Rafael on 8 of the 15 factors compared between the two stocks.

Get Rafael News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RFL vs. The Competition

Export

Metric	Rafael	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$133.12M	$12.15B	$7.20B	$24.18B
Dividend Yield	N/A	2.62%	2.54%	3.71%
P/E Ratio	-3.71	787.65	273.16	29.99
Price / Sales	133.71	792.89	605.01	22.59
Price / Cash	N/A	91.95	76.74	32.24
Price / Book	1.32	11.97	12.98	7.67
Net Income	-$30.52M	$2.83B	$3.48B	$1.07B
7 Day Performance	16.67%	0.39%	0.13%	-0.32%
1 Month Performance	25.94%	5.34%	7.08%	1.84%
1 Year Performance	70.85%	6.05%	24.67%	13.37%

Rafael Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RFL Rafael	0.1223 of 5 stars	$2.52 +6.3%	N/A	+70.8%	$133.12M	$980K	N/A	20	Analyst Forecast High Trading Volume
RLMD Relmada Therapeutics	2.6206 of 5 stars	$4.38 -3.1%	$12.00 +174.0%	+286.6%	$467.22M	N/A	N/A	10	Positive News
BIOA BioAge Labs	3.825 of 5 stars	$9.85 -2.3%	$36.57 +271.3%	+95.7%	$452.12M	$8.99M	N/A	N/A	Positive News
CGC Canopy Growth	0.8199 of 5 stars	$1.00 -1.3%	N/A	-44.5%	$447.82M	$251.01M	N/A	1,128	Analyst Upgrade
FENC Adherex Technologies	4.4486 of 5 stars	$12.30 +4.5%	$17.00 +38.2%	+38.3%	$431.24M	$44.64M	N/A	10	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RFL) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rafael (RFL) Competitors

RFL vs. RLMD, BIOA, CGC, FENC, and AVIR

How does Rafael compare to Relmada Therapeutics?

Summary

How does Rafael compare to BioAge Labs?

Summary

How does Rafael compare to Canopy Growth?

Summary

How does Rafael compare to Adherex Technologies?

Summary

How does Rafael compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFL vs. The Competition

Rafael Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rafael (RFL) Competitors

RFL vs. RLMD, BIOA, CGC, FENC, and AVIR

How does Rafael compare to Relmada Therapeutics?

Do insiders & institutionals hold more shares of RLMD or RFL?

Do analysts prefer RLMD or RFL?

Does the media favor RLMD or RFL?

Is RLMD or RFL more profitable?

Which has more risk and volatility, RLMD or RFL?

Which has stronger valuation and earnings, RLMD or RFL?

Summary

How does Rafael compare to BioAge Labs?

Do analysts recommend BIOA or RFL?

Do insiders and institutionals believe in BIOA or RFL?

Which has more risk and volatility, BIOA or RFL?

Which has better earnings & valuation, BIOA or RFL?

Does the media prefer BIOA or RFL?

Is BIOA or RFL more profitable?

Summary

How does Rafael compare to Canopy Growth?

Is RFL or CGC more profitable?

Which has more risk and volatility, RFL or CGC?

Do analysts rate RFL or CGC?

Which has stronger earnings and valuation, RFL or CGC?

Do insiders & institutionals hold more shares of RFL or CGC?

Does the media favor RFL or CGC?

Summary

How does Rafael compare to Adherex Technologies?

Is FENC or RFL more profitable?

Which has more volatility and risk, FENC or RFL?

Do institutionals & insiders believe in FENC or RFL?

Do analysts prefer FENC or RFL?

Which has preferable valuation and earnings, FENC or RFL?

Does the media prefer FENC or RFL?

Summary

How does Rafael compare to Atea Pharmaceuticals?

Does the media favor RFL or AVIR?

Do insiders and institutionals have more ownership in RFL or AVIR?

Which has preferable earnings and valuation, RFL or AVIR?

Is RFL or AVIR more profitable?

Which has more volatility & risk, RFL or AVIR?

Do analysts prefer RFL or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFL vs. The Competition

Rafael Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools